4.7 Article

A dominant-negative p65 PAK peptide inhibits angiogenesis

Journal

CIRCULATION RESEARCH
Volume 90, Issue 6, Pages 697-702

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.RES.0000014227.76102.5D

Keywords

endothelial cells; p21-activated kinase; cell contractility; endothelial tube-forming assay

Funding

  1. NCI NIH HHS [P01 CA78045, R01 CA45726, CA50286] Funding Source: Medline
  2. NHLBI NIH HHS [P01HL57900] Funding Source: Medline

Ask authors/readers for more resources

PAK1 is a protein kinase downstream of the small GTPases Rac and Cdc42 that previous work has implicated in endothelial cell migration via modulation of cell contraction. The first proline-rich region of PAK that binds to an SH3 domain from the adapter protein NCK was responsible for these dominant-negative effects. To test the role of PAK in angiogenesis, we prepared a peptide in which the proline-rich region was fused to the polybasic sequence from the HIV Tat protein to facilitate entry into cells. We show that the short peptide selectively binds NCK, whereas a mutant peptide does not. Treatment of cells with the PAK peptide but not the control peptide disrupts localization of PAK. This peptide specifically inhibited endothelial cell migration and contractility similarly to full-length dominant-negative PAK. In an in vitro tube-forming assay, the PAK peptide specifically blocked formation of multicellular networks. In an in vivo chick chorioallantoic membrane assay, the PAK peptide specifically blocked angiogenesis. These results, therefore, suggest a role for PAK in angiogenesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available